Sign in
CompletedPhase 1

Artesunate Ointment for the Treatment of High Grade Vulvar Intraepithelial Neoplasia (HSIL VIN2/3)

Key facts

Who runs it
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Where
Baltimore, Cleveland, and Mayfield Heights, United StatesSee the 4 sites
Trial code
Status
Completed
Phase
Phase 1
People taking part
15 people enrolled
Started
17 Apr 2019
Ended
3 Dec 2024
Type of study
Interventional, 3 groups
Treatments tested
  • artesunate ointment 40%
Record updated
4 December 2024

Who can take part

Age
18 years to 100 years
Sex
Women only
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Colposcopically-directed biopsy diagnosis of high-grade vulvar dysplasia (VIN2, VIN3, VIN2/3, HSIL), including both new and recurrent disease
  • Females of childbearing potential: negative urine pregnancy test
  • Ability to provide informed consent
  • Ability to collaborate with planned follow-up (transportation, compliance history, etc.)
  • Use of contraception through the study exit visit (week 28)

Who cannot take part

  • Concomitant use of any topical immune modulating agents e.g. imiquimod, Aldara ®
  • Currently receiving systemic chemotherapy or radiation therapy for another cancer
  • Concurrent dermatological disorders involving the vulva (i.e., herpes, ulceration secondary to Crohn's disease) or vulvar dermatosis (i.e., lichen planus, lichen sclerosus, or lichen simplex chronicus)
  • Cluster of differentiation 4 (CD4) count < 200 at the time of screening for eligibility
  • Unable to provide informed consent
  • Pregnant females
  • Women weighing less than 50 kg

Where in United States

  • Johns Hopkins Outpatient CenterBaltimore, United States
  • Cleveland Clinic Fairview HospitalCleveland, United States
  • Cleveland Clinic Foundation Main CampusCleveland, United States
  • Cleveland Clinic - Hillcrest HospitalMayfield Heights, United States

About the trial

What the trial wants to find out

This is a Phase I, proof-of-concept treatment study to evaluate the safety, tolerability and feasibility of topical artesunate ointment to treat high grade vulvar intraepithelial neoplasia (HSIL VIN2/3).

The 3 groups in the trial

  • Artesunate ointment 40%, 1 cycleTreatment being tested

    Patients enrolled in this treatment group will receive one 5-day cycle of artesunate ointment applied topically to the vulva at week 0.

    Treatment: artesunate ointment 40%

  • Artesunate ointment 40%, 2 cyclesTreatment being tested

    Patients enrolled in this treatment group will receive two 5-day cycles of artesunate ointment applied topically to the vulva at weeks 0 and 2.

    Treatment: artesunate ointment 40%

  • Artesunate ointment 40%, 3 cyclesTreatment being tested

    Patients enrolled in this treatment group will receive three 5-day cycles of artesunate ointment applied topically to the vulva at weeks 0, 2, and 4.

    Treatment: artesunate ointment 40%

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase I Proof-of-Concept Study of Artesunate Ointment for the Treatment of Patients With High-Grade Vulvar Intraepithelial Neoplasia (HSIL VIN 2/3)
Record updated
4 December 2024